// App-Quantinova.ai

e23040 : Circulating tumour DNA carrying patient-specific mutations in TP53 as an early response biomarker in relapsed high grade serous ovarian cancer.

Researchers

Presenter

  • Christine A. Parkinson

Principal Investigators

  • Davina Gale

  • Anna Piskorz

  • Charlotte Hodgkin

  • Heather Biggs

  • Helen Addley

  • Penny Moyle

  • Sue Freeman

  • Evis Sala

  • Karen Hosking

  • Ioannis Gounaris

  • Mercedes Jimenez-Linan

  • Helena Margaret Earl

  • Wendi Qian

  • Nitzan Rosenfeld

  • James D. Brenton

Medical Centers

  • Cancer Research UK Cambridge Institute, University of Cambridge., Cambridge, United Kingdom

  • Cambridge University Hospital NHS Foundation Trust and Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, United Kingdom

  • Cambridge University Hospitals NHS Foundation Trust, and Cambridge Breast Unit, Cambridge, United Kingdom

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Department of Oncology, University of Cambridge, Cambridge, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • High grade serous ovarian cancer

Biomarkers

  • Tumor protein p53

  • Carbohydrate antigen 125

  • Circulating DNA

Drug/Treatment

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved